恩替卡韦片联合胸腺肽α1治疗HBeAg阳性乙型肝炎疗效分析

Therapeutic efficacy of the combination of entecavir and thymosin alpha 1 on patients with HBeAg-positive chronic hepatitis B

目的 探讨恩替卡韦片联合胸腺肽α1治疗HBeAg阳性慢性乙型肝炎的疗效。方法 140例慢性乙型肝炎患者随机分为2组,治疗组(72例)口服恩替卡韦片,0.5mg/次,1次/d,同时给予胸腺肽α1皮下注射,1.6mg/次,2次/周;对照组(68例)单用恩替卡韦片口服,0.5mg/次,1次/d,2组均连用48周。结果 治疗组HBeAg转阴率为58.33%,HBeAg/抗HBe转换率为38.89%,明显高于对照组(23.53%、11.76%),差异有统计学意义(P均<0.01)。2组HBV DNA转阴率及ALT复常率差异无统计学意义(P均>0.05)。结论 恩替卡韦片联合胸腺肽α1治疗慢性乙型肝炎可提高HBeAg转阴率和HBeAg/抗HBe血清转换率。

Objective To investigate the therapeutic efficacy of the combination of entecavir （ETV） and thymosin alpha 1 on patients with HBeAg-positive chronic hepatitis B （CHB）. Methods Totally 140 patients with HBeAg-positive CHB were random- ized into a treatment group （n=72） and a control group （n=68）. The patients in the treatment group were administered with ETV 0.5 mg once daily and subcutaneously injected with thymosin alpha 1 1.6 mg per time twice a week for 48 weeks, while the patients in the control group were only administered with 0.5 mg once daily for 48 weeks. Results The treatment group displayed significantly higher HBeAg negative rate （58.33%） and higher HBeAg/anti-HBe seroconversion rate （38.89%） compared with the control group （23.53% and 11,76%, respectively）, and the differences between the two groups were significant （P〈0.01）. The differences in both HBV DNA negative rate and ALT normalization rate were not significant between the two groups （P〉0.05）. Conclusion The combi- nation of ETV and thymosin alpha 1 can improve HBeAg negative rate and HBeAg/anti-HBe seroconversion rate in patients with HBeAg-positive CHB.